Additionally, T-DM1 received an extension of indication in the adjuvant setting, in particular for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2-targeted therapy. Here, ERBB2 is linked to breast carcinoma.